Spyre Therapeutics (SYRE) Non-Current Assets (2015 - 2025)
Spyre Therapeutics posted quarterly Non-Current Assets of $10000.0 for Q1 2025, down 96.96% year-on-year from $329000.0 in Q1 2024, and little changed on a QoQ basis from $10000.0 in Q4 2024.
Spyre Therapeutics (SYRE) has 11 years of Non-Current Assets data on file, last reported at $10000.0 in Q1 2025.
- For the quarter ending Q1 2025, Non-Current Assets fell 96.96% year-over-year to $10000.0; the trailing twelve-month figure through Dec 2025 stood at $10000.0 (down 98.53% YoY), and the FY2024 full-year result was $10000.0, down 96.98% from the prior year.
- Non-Current Assets for Q1 2025 stood at $10000.0, roughly flat from $10000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $12.6 million in Q2 2021 and bottomed at $10000.0 in Q3 2024.
- The 5-year median for Non-Current Assets is $8.1 million (2023), against an average of $5.9 million.
- The widest annual swing landed in 2021, when Non-Current Assets climbed 16.03%; it then plunged 99.24% in 2024.
- A 5-year view of Non-Current Assets shows it stood at $11.0 million in 2021, then declined by 19.47% to $8.9 million in 2022, then tumbled by 96.28% to $331000.0 in 2023, then tumbled by 96.98% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
- The last three Non-Current Assets figures came in at $10000.0 (Q1 2025), $10000.0 (Q4 2024), and $10000.0 (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 331,000.00 |
| Mar 31, 2024 | 329,000.00 |
| Dec 31, 2023 | 331,000.00 |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 3.64 Mn |
| Mar 31, 2023 | 8.08 Mn |
| Dec 31, 2022 | 8.89 Mn |
| Sep 30, 2022 | 9.35 Mn |
| Jun 30, 2022 | 10.06 Mn |
| Mar 31, 2022 | 10.57 Mn |
| Dec 31, 2021 | 11.04 Mn |
| Sep 30, 2021 | 11.55 Mn |
| Jun 30, 2021 | 12.61 Mn |
| Mar 31, 2021 | 12.20 Mn |
| Dec 31, 2020 | 11.83 Mn |
| Sep 30, 2020 | 11.23 Mn |
| Jun 30, 2020 | 11.05 Mn |
| Mar 31, 2020 | 10.52 Mn |
| Dec 31, 2019 | 8.68 Mn |
| Sep 30, 2019 | 7.47 Mn |
| Jun 30, 2019 | 7.56 Mn |
| Mar 31, 2019 | 1.70 Mn |
| Dec 31, 2018 | 1.07 Mn |
| Sep 30, 2018 | 895,000.00 |
| Jun 30, 2018 | 825,000.00 |
| Mar 31, 2018 | 943,000.00 |
| Dec 31, 2017 | 1.09 Mn |
| Sep 30, 2017 | 983,000.00 |
| Jun 30, 2017 | 941,000.00 |
| Mar 31, 2017 | 962,000.00 |
| Dec 31, 2016 | 639,000.00 |
| Sep 30, 2016 | 382,000.00 |
| Jun 30, 2016 | 395,000.00 |
| Mar 31, 2016 | 339,000.00 |
| Dec 31, 2015 | 368,000.00 |